Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05273307 · ClinicalTrials.gov registry record · Phase 3

Addressing Taste Dysfunction With Miraculin in Head and Neck Cancer Patients Receiving Radiation Therapy

A Phase 3 study of Head and Neck Cancer and Taste Dysfunction, sponsored by University of California, San Francisco.

Recruiting
Registry status
Phase 3
Development phase
40
Enrollment target
1
Study location

NCT05273307 is a Phase 3 study of Head and Neck Cancer and Taste Dysfunction that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 40 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05273307, a Phase 3 study of Head and Neck Cancer and Taste Dysfunction, is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
Phase 3
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

Patients diagnosed with head and neck cancer who receive radiation therapy with and without chemotherapy develop altered sense of taste due to treatment effect, which typically arises in the second week of radiation therapy and progresses throughout the course of treatment. While some symptoms such as pain, mucositis, and xerostomia can be managed with pain medications and saliva replacements, taste alteration has an earlier onset and is a more difficult symptom to readily address and intervene upon. There are no effective established interventions for taste, although this is a major issue in the patient experience. The investigator will be examining they hypothesis that a miracle fruit cube would yield the greatest benefit to improve taste dysfunction in the beginning half of radiation treatment when taste function is decreased but not absent.

Conditions Studied

Head and Neck Cancer Taste Dysfunction

Interventions

  • DIETARY_SUPPLEMENT Miraculin
  • DIETARY_SUPPLEMENT Miracle Fruit Placebo Cube

Study Locations (1)

California

  • University of California, San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2022-03-04
Est. Completion 2026-09-30
Phase Phase 3

Sponsor

University of California, San Francisco

1,713 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05273307

The ClinicalTrials.gov registry entry for NCT05273307 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (85% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 2 interventions - of which Miraculin is the first listed.

NCT05273307 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05273307 about?

NCT05273307 is a clinical study titled "Addressing Taste Dysfunction With Miraculin in Head and Neck Cancer Patients Receiving Radiation Therapy". Patients diagnosed with head and neck cancer who receive radiation therapy with and without chemotherapy develop altered sense of taste due to treatment effect, which typically arises in the second week of radiation therapy and progresses throughout the course of treatment. While some symptoms such ...

What is the current status of trial NCT05273307?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2022-03-04. Estimated completion is 2026-09-30.

What conditions does trial NCT05273307 study?

This clinical trial studies the following conditions: Head and Neck Cancer, Taste Dysfunction.

What interventions are being tested in trial NCT05273307?

The interventions under investigation include: Miraculin (DIETARY_SUPPLEMENT), Miracle Fruit Placebo Cube (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT05273307?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05273307 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Head and Neck Cancer

All registered trials for this condition

Taste Dysfunction

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.